Cingulate Inc. (CING)
US — Healthcare Sector
Automate Your Wheel Strategy on CING
With Tiblio's Option Bot, you can configure your own wheel strategy including CING - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CING
- Rev/Share 0.0
- Book/Share 3165.9525
- PB 0.0027
- Debt/Equity 0.0056
- CurrentRatio 1.8709
- ROIC -0.9544
- MktCap 18893423.0
- FreeCF/Share -1266.3156
- PFCF -0.0041
- PE -0.0023
- Debt/Assets 0.0027
- DivYield 0
- ROE -4.7325
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CING | ROTH MKM | -- | Buy | -- | $12 | Jan. 10, 2025 |
News
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
CING
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission
Read More
About Cingulate Inc. (CING)
- IPO Date 2021-12-08
- Website https://www.cingulate.com
- Industry Biotechnology
- CEO Dr. Shane J. Schaffer Pharm.D.
- Employees 13
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.